Tom W J Huizinga Selected Research

Rituximab (Mabthera)

11/2022	Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
1/2020	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
1/2017	Rituximab in early systemic sclerosis.
11/2014	Belimumab after rituximab as maintenance therapy in lupus nephritis.
9/2010	Rheumatoid arthritis.
6/2009	Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
11/2008	Rituximab in relapsing Graves' disease, a phase II study.
12/2007	Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tom W J Huizinga Research Topics

Disease

180	Rheumatoid Arthritis 04/2024 - 03/2003
44	Arthritis (Polyarthritis) 01/2022 - 02/2004
33	Inflammation (Inflammations) 01/2023 - 06/2004
21	Systemic Scleroderma (Systemic Sclerosis) 01/2023 - 10/2003
12	Osteoarthritis 12/2018 - 08/2003
10	Autoimmune Diseases (Autoimmune Disease) 04/2024 - 12/2004
9	Disease Progression 01/2023 - 07/2004
9	Arthralgia (Joint Pain) 01/2022 - 04/2013
8	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023 - 04/2002
8	Synovitis 12/2022 - 07/2010
7	Pain (Aches) 12/2018 - 10/2008
7	Experimental Arthritis 01/2016 - 10/2004
6	Necrosis 01/2020 - 02/2007
5	Fibrosis (Cirrhosis) 11/2020 - 10/2003
5	Infections 01/2016 - 11/2005
4	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 01/2017
4	Neoplasms (Cancer) 01/2019 - 07/2003
3	Lupus Nephritis 11/2022 - 11/2014
3	Rheumatic Diseases (Rheumatism) 10/2022 - 02/2012
3	Central Nervous System Lupus Vasculitis 01/2017 - 01/2006
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2016 - 06/2004
3	Wounds and Injuries (Trauma) 01/2013 - 03/2003
2	Psoriatic Arthritis 01/2023 - 11/2015
2	digital ulcers 01/2023 - 01/2023
2	Axial Spondyloarthritis 01/2023 - 11/2017
2	Connective Tissue Diseases (Connective Tissue Disease) 01/2023 - 01/2023
2	Diffuse Scleroderma (Progressive Systemic Sclerosis) 10/2022 - 01/2022
2	Fatigue 06/2021 - 01/2015
2	Osteoporosis 01/2021 - 01/2016
2	Neutropenia 01/2018 - 09/2014
2	Tenosynovitis 12/2016 - 05/2015

Drug/Important Bio-Agent (IBA)

53	AntibodiesIBA 10/2023 - 02/2004
50	AutoantibodiesIBA 04/2024 - 02/2004
43	Proteins (Proteins, Gene)FDA Link 10/2023 - 01/2005
39	Anti-Citrullinated Protein AntibodiesIBA 04/2024 - 07/2004
31	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 04/2006
22	Antirheumatic Agents (DMARD)IBA 01/2023 - 10/2006
19	AntigensIBA 04/2024 - 10/2004
19	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 01/2002
18	Immunoglobulin G (IgG)IBA 04/2024 - 01/2006
14	acetyl 4-aminosalicylic acidIBA 01/2023 - 01/2007
12	Peptides (Polypeptides)IBA 10/2016 - 07/2004
11	EpitopesIBA 01/2017 - 05/2005
9	Prednisone (Sone)FDA LinkGeneric 04/2024 - 05/2009
9	Rheumatoid FactorIBA 01/2019 - 01/2007
9	Interleukin-10 (Interleukin 10)IBA 08/2005 - 04/2002
8	Immunoglobulin M (IgM)IBA 10/2023 - 01/2006
8	Rituximab (Mabthera)FDA Link 11/2022 - 12/2007
8	Abatacept (Orencia)FDA Link 01/2020 - 09/2010
7	amsonic acid (DAS)IBA 04/2024 - 06/2009
7	CytokinesIBA 01/2016 - 01/2002
7	EnzymesIBA 08/2015 - 10/2003
7	cyclic citrullinated peptideIBA 04/2013 - 01/2005
5	GlucocorticoidsIBA 01/2023 - 01/2016
5	Etanercept (Enbrel)FDA Link 01/2020 - 02/2007
5	HLA-DRB1 Chains (HLA DRB1)IBA 10/2016 - 10/2005
5	HLA Antigens (Human Leukocyte Antigens)IBA 09/2015 - 05/2005
5	CollagenIBA 08/2015 - 07/2004
5	4-hexyloxyaniline (HOA)IBA 05/2014 - 07/2010
4	anti-scl-70 autoantibodiesIBA 01/2023 - 05/2020
4	Polysaccharides (Glycans)IBA 02/2022 - 05/2011
4	Adalimumab (Humira)FDA Link 03/2021 - 02/2006
4	ametantrone (HAQ)IBA 01/2020 - 10/2013
4	sarilumabIBA 01/2020 - 09/2014
4	C-Reactive ProteinIBA 10/2016 - 09/2013
4	VimentinIBA 07/2011 - 08/2009
3	AutoantigensIBA 04/2024 - 12/2004
3	Immunoglobulin A (IgA)IBA 01/2023 - 11/2020
3	Prednisolone (Predate)FDA LinkGeneric 11/2022 - 02/2007
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 02/2016
3	tocilizumab (atlizumab)FDA Link 01/2020 - 09/2010
3	Infliximab (Remicade)FDA Link 01/2020 - 02/2007
3	Certolizumab Pegol FDA Link 01/2020 - 12/2012
3	Fibrinogen (Factor I)FDA Link 10/2014 - 01/2011
3	AdiponectinIBA 05/2014 - 07/2011
3	TNF Receptor-Associated Factor 1IBA 02/2011 - 09/2007
3	Messenger RNA (mRNA)IBA 06/2010 - 10/2003
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 05/2005 - 05/2002
3	Interleukin-1beta (Interleukin 1 beta)IBA 05/2005 - 05/2002
3	LipopolysaccharidesIBA 05/2005 - 10/2004
2	Antiphospholipid AntibodiesIBA 01/2024 - 06/2013
2	insulin receptor-related receptor (IRR)IBA 01/2023 - 12/2022
2	belimumabIBA 11/2022 - 11/2014
2	anticentromere antibodyIBA 12/2021 - 01/2021
2	Biosimilar PharmaceuticalsIBA 03/2021 - 01/2020
2	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2021 - 08/2017
2	tofacitinibIBA 01/2020 - 01/2016
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 01/2018
2	Janus Kinase InhibitorsIBA 01/2020 - 01/2016
2	Alanine Transaminase (SGPT)IBA 01/2018 - 10/2008
2	Carbon MonoxideIBA 01/2017 - 01/2015
2	CitrullineIBA 10/2015 - 02/2012
2	ImmunosorbentsIBA 08/2015 - 07/2011
2	Collagen Type II (Type II Collagen)IBA 08/2015 - 01/2014
2	GadoliniumIBA 05/2015 - 10/2014

Therapy/Procedure

30	Therapeutics 12/2022 - 04/2005
3	Remission Induction 01/2018 - 09/2012
3	Injections 10/2010 - 09/2006
2	Stem Cell Transplantation 10/2022 - 01/2007
2	Biological Therapy 01/2017 - 03/2013